Data Article

Data on the proliferation and differentiation of C2C12 myoblast treated with branched-chain ketoacid dehydrogenase kinase inhibitor

Yoriko Sato\textsuperscript{a}, Hayato Tate\textsuperscript{b}, Fumiaki Yoshizawa\textsuperscript{b}, Yusuke Sato\textsuperscript{b,\ast}

\textsuperscript{a} Center for Bioscience Research and Education, Utsunomiya University, Tochigi, Japan
\textsuperscript{b} Department of Agrobiology and Bioresources, Utsunomiya University, Tochigi, Japan

\textbf{A R T I C L E   I N F O}

\textit{Article history:}
Received 11 April 2020
Revised 16 May 2020
Accepted 19 May 2020
Available online 26 May 2020

\textbf{Keywords:}
C2C12 myoblast
Proliferation
Differentiation
Branched chain amino acids
Branched chain ketoacid dehydrogenase kinase inhibitor

\textbf{A B S T R A C T}

The catabolism of branched chain amino acids (BCAAs) is mainly carried out in skeletal muscle myofibers. It is mediated by branched chain aminotransferase 2 and branched chain alpha ketoacid dehydrogenase (BCKDH) in mitochondria for energy supply, especially during exercise. BCKDH kinase (BCKDK) is a negative regulator of BCAAs catabolism by its inhibitory phosphorylation of the BCKDH E1a subunit. The data presented in this article are related to the research article that we previously have reported entitled “Energy metabolism profile of the effects of amino acid treatment on skeletal muscle cells: Leucine inhibits glycolysis of myotubes” (Suzuki et al., 2020)\textsuperscript{[1]}. In this report, we have demonstrated that 1hour treatment of BT2, an inhibitor of BCKDK, decreased the glycolysis of C2C12 differentiated myotubes compared to the control. Although BCAAs metabolism is basically assumed to be carried out in differentiated myofibers, BCKDK is expressed in both undifferentiated myoblasts and differentiated myotubes, and the biological and physiological significance of BCAAs metabolism in myoblasts is still unclear. Present data demonstrate an in vitro assessment of BT2 on C2C12 myoblasts proliferation and differentiation. The data suggest that activation of BCAAs catabolism

\textsuperscript{\ast} Corresponding author.
\textit{E-mail address:} ysato@cc.utsunomiya-u.ac.jp (Y. Sato).

https://doi.org/10.1016/j.dib.2020.105766
2352-3409/© 2020 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY license. (http://creativecommons.org/licenses/by/4.0/)
The BCKDK inhibitor BT2 impairs C2C12 myoblasts proliferation and differentiation.

© 2020 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY license. (http://creativecommons.org/licenses/by/4.0/)

Specifications table

| Subject                     | Cell Biology                     |
|-----------------------------|----------------------------------|
| Specific subject area       | Muscle cell biology, Branched chain amino acids metabolism |
| Type of data                | Graph                            |
| How data were acquired      | Immunoblot, qRT-PCR, Microscopy, Cell proliferation assay |
| Data format                 | Analyzed                         |
| Parameters for data collection | C2C12 myoblasts were treated with BT2 to activate branched chain amino acids metabolism both during proliferation and differentiation |
| Description of data collection | C2C12 myoblasts were treated with BT2 (0-100 μM). The effect of BT2 on cell proliferation was evaluated by Cell Counting Kit-8 (CCK-8). The effect of BT2 on myogenic differentiation was evaluated by measuring the differentiation markers using immunoblot and qRT-PCR. |
| Data source location        | Utsunomiya university            |
| Data accessibility          | Data are presented with this article |
| Related research article    | Reiko Suzuki, Yoriko Sato, Kodwo Amuzuah Obeng, Daisuke Suzuki, Yusuke Komiya, Shin-ichi Adachi, Fumiaki Yoshizawa, Yusuke Sato |

Value of the data

- The data provide the possibility that activation of branched chain amino acids catabolism by the BCKDK inhibitor BT2 may suppress C2C12 myoblasts proliferation and differentiation.
- Since BCAAs metabolism is basically assumed to be carried out in differentiated myofibers, the biological and physiological significance of BCAAs metabolism in myoblasts is still unclear.
- The data is valuable for researchers interested in the relationship between branched chain amino acids metabolism and physiology of skeletal muscle cell.
- The data help researchers design experiments examining C2C12 myoblasts proliferation and differentiation in response to drug.

1. Data Description

Recently we have reported that activation of branched chain amino acids catabolism by BT2, a BCKDK (branched chain ketoacid dehydrogenase kinase) inhibitor, impaired the glycolysis of C2C12 myotubes [1,2]. BCKDK is expressed in both C2C12 myoblasts and differentiated myotubes. Here, we present data regarding the effect of BT2 on C2C12 myoblast proliferation and myogenic differentiation. The data in Fig. 1 show the comparison of cell proliferation rate between control and BT2-treated myoblasts. Data in Fig. 1 were obtained by Cell Counting Kit-8. The data in Fig. 2 show the comparison of myogenic differentiation between control and BT2-treated myoblasts after induction of differentiation by reducing the serum concentration. Data in Fig. 2 were obtained by immunoblot, qRT-PCR and microscopy.
Fig. 1. The effect of BT2 on C2C12 myoblast proliferation. C2C12 myoblasts were cultured in DMEM containing 1% FBS and BT2 (10, 50, 100 μM). Cell Counting Kit-8 was used to measure the relative number of myoblasts. a) Relative cell proliferation rates were presented as percentage of 4h. b) Relative cell number 24 h after the treatment of BT2 was presented. Different superscripts indicate a significant difference between 2 groups. All assessments of significance were performed with 1-way ANOVA with Tukey post hoc test (p < 0.05). Values are means ± SEM (n = 12–14).

2. Experimental Design, Materials, and Methods

To investigate the effect of BCAAs catabolism on myoblasts proliferation and myogenic differentiation, C2C12 myoblasts were treated with BT2, an inhibitor for BCKDK. For the evaluation of myoblasts proliferation, myoblasts were cultured for 24 hours and then relative cell proliferation rate was measured by Cell Counting Kit-8. For the evaluation of myogenic differentiation, myoblasts were collected at day 0, 2 and 5 after induction of differentiation and then myogenic marker genes and protein expression were measured by qRT-PCR and immunoblot.

2.1. Cell culture and reagents

C2C12 myoblasts were purchased from ATCC (Manassas, VA, USA). C2C12 myoblasts at early passage (3-10) were used for experiment. Cells were maintained in DMEM supplemented with 10% fetal bovine serum, 1% penicillin/streptomycin mixture at 37 °C with 5% CO₂. For myogenic differentiation, myoblasts were cultured in 2% HS-DMEM until myotubes formed (5 days) after the cells reached 80-90% confluency. For gene and protein expression analyses, cells were seeded on 12-well miniplates (n = 6, each group) or 6-well miniplates (n = 3, each group), respectively. BT2 (3,6-dichlorobenz[b]thiophene-2-carboxylic acid) (Axon Medchem, Groningen, Netherland) was used to inhibit BCKDC kinase for the activation of BCAAs catabolism [2].
2.2. Cell proliferation assay

Cell proliferation assay was assessed with a Cell Counting Kit-8 assay (Dojindo Laboratories, Kumamoto, Japan) according to the manufacture’s protocol with slight modifications [3]. C2C12 myoblasts were seeded in 96-well miniplates at a density of 3000 cells/well in DMEM containing 10% FBS for 24 hours. The culture medium was removed and replaced with DMEM containing 1% FBS and BT2 (10-100 μM). After 24 hours of culture, cell proliferation was assessed using Cell Counting Kit-8.
2.3. RNA extraction and quantitative real-time polymerase chain reaction

Expression of target and reference genes was measured using a quantitative real-time polymerase chain reaction (qRT-PCR) according to the previous report [4]. Gapdh was used as the reference gene. The significance of differences in mRNA was calculated by 2-ΔΔCt method. Total RNAs were isolated from 6 individual wells of cultured C2C12 myoblasts according to the regular Trizol-chloroform protocol. cDNA was synthesized from 1 μg of total RNA by a reverse-transcriptase iScript (Bio-Rad, Hercules, CA, USA), and qRT-PCR was performed using LightCycler 96 (Roche Diagnostics, Mannheim, Germany). The primer sets were designed by Primer3. The primer sequences are as follows: Gapdh forward, TGTCCATCAACGACCCCTTC; Gapdh reverse, TTGTCTGATGATCGTTGGC; Myog forward, ACCTCTCTTCACCTTCAG; Myog reverse, CACCACAGACTTCTCT; Myh3 forward, CAATAAATGCACGGCAAAGAC; Myh3 reverse, CTTGCTCACTC-CTCGCTTTCA.

2.4. Protein extraction and immunoblot analyses

Proteins were extracted from 3 individual wells of cultured C2C12 myoblasts of each group. The samples were homogenized in SDS sample buffer containing 125 mm Tris–HCl pH 6.8, 5% β-mercaptoethanol, 2% SDS and 10% glycerol. Extracted proteins were separated on acrylamide gels, and then transferred onto PVDF membranes (GE Healthcare). A blocking solution of 5% BSA was used. The chemidoc XRS Imager (Bio-rad) was used for evaluating the detected bands. Total myosin heavy chain was measured by MF20 antibody (eBioscience, 14–6503–82, dilution 1:1000) to determine the differentiation level of C2C12 myoblasts. β-actin was used as internal standard (Cell Signaling Technology, #4967, dilution 1:1000).

2.5. Statistical analysis

All data are presented as means ± SEM. P values less than 0.05 were considered significant and all assessment of significance was performed with unpaired 2-tailed Student’s t-test or 1-way analysis of variance (ANOVA) with Tukey post hoc test using Prism6 (GraphPad Software, La Jolla, CA, USA).

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships which have, or could be perceived to have, influenced the work reported in this article.

Acknowledgments

This work was partially supported by Grants-in-Aid for JSPS Fellows (Grant number 17H05040 Yusuke Sato) from the Ministry of Education, Science, Sports and Culture of Japan. We are very grateful to Reiko Suzuki for valuable discussion.

Supplementary materials

Supplementary material associated with this article can be found, in the online version, at doi:10.1016/j.dib.2020.105766.
References

[1] R. Suzuki, Y. Sato, K.A. Obeng, D. Suzuki, Y. Komiya, S.-i. Adachi, F. Yoshizawa, Y. Sato, Energy metabolism profile of the effects of amino acid treatment on skeletal muscle cells: Leucine inhibits glycolysis of myotubes, Nutrition (2020). 10.1016/j.nut.2020.110794.

[2] S.C. Tso, W.J. Gui, C.Y. Wu, J.L. Chuang, X. Qi, K.J. Skvora, K. Dork, A.L. Wallace, L.K. Morlock, B.H. Lee, S.M. Hutson, S.C. Strom, N.S. Williams, U.K. Tambar, R.M. Wynn, D.T. Chuang, Benzothiophene carboxylate derivatives as novel allosteric inhibitors of branched-chain alpha-ketoacid dehydrogenase kinase, J Biol Chem 289 (2014) 20583–20593, doi:10.1074/jbc.M114.569251.

[3] W. Mizunoya, A. Tashima, Y. Sato, R. Tatsumi, Y. Ikeuchi, The growth-promoting activity of egg white proteins in the C2C12 myoblast cell line, Anim Sci J 86 (2015) 194–199, doi:10.1111/asj.12257.

[4] Y. Sato, Y. Sato, K.A. Obeng, F. Yoshizawa, Acute oral administration of L-leucine upregulates slow-fiber- and mitochondria-related genes in skeletal muscle of rats, Nutr Res 57 (2018) 36–44, doi:10.1016/j.nutres.2018.05.006.